Skip to main content
SpringerLink
Log in

Malignant Mesothelioma: Pathology

  • Chapter
  • First Online:
Occupational Cancers

  • 1046 Accesses

Abstract

The majority of malignant mesotheliomas (MMs) occur in the pleura, but they may also arise in the peritoneum, the pericardium, or the tunica vaginalis testis. MM is a great mimic and its morphology is so variable that a vast number of different primary and secondary tumors of the body cavities must be considered in differential diagnosis. Another diagnostic challenge is distinguishing MM from reactive lesions, i.e., epithelioid MM from benign mesothelial hyperplasia and sarcomatoid or desmoplastic MM from fibrous pleuritis. Molecular markers, such as loss of BAP1 and homozygous deletion of 9p21 chromosomal region, have a specificity of 100% and, if combined, a sensitivity of appr. 80% in the diagnosis of malignant mesothelioma. Diffuse MM exhibiting any subtype or morphological pattern may have asbestos etiology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Allen TC, Cagle PT, Churg AM, Colby TV, Gibbs AR, Hammar SP, Corson JM, Grimes MM, Ordonez NG, Roggli V, Travis WD, Wick MR. Localized malignant mesothelioma. Am J Surg Pathol. 2005;29:866–73.

    Article  PubMed  Google Scholar 

  2. Galateau-Salle F, editor. Pathology of malignant mesothelioma. London: Springer; 2006.

    Google Scholar 

  3. Husain AN, Colby TV, Ordonez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Salle F, Gibbs AR, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR. Guidelines for pathologic diagnosis of malignant mesothelioma. 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142:89–108.

    Article  CAS  PubMed  Google Scholar 

  4. Hwang HC, Pyott S, Rodriguez S, Cindric A, Carr A, Michelsen C, Thompson K, Tse CH, Gown AM, Churg A. BAP1 immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas. Am J Surg Pathol. 2016;40(5):714–8.

    Article  PubMed  Google Scholar 

  5. Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 2016;40(1):120–6.

    Article  PubMed  Google Scholar 

  6. Kinoshita Y, Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Hiroshima K, Oda Y, Nabeshima K. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma. Cancer Cytopathol. 2018;126:54–63.

    Article  CAS  PubMed  Google Scholar 

  7. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, editors. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer; 2015.

    Google Scholar 

  8. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145–52.

    Article  CAS  PubMed  Google Scholar 

  9. Gorini G, De Gregorio G, Silvestri S, Chellini E, Cupelli V, Seniori Costantini A. Survival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988–2000: a population-based study. Eur J Cancer Prev. 2005;14:195–9.

    Article  CAS  PubMed  Google Scholar 

  10. Balduyck B, Trousse D, Nakas A, Martin-Ucar AE, Edwards J, Waller DA. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? Ann Thorac Surg. 2010;89:907–11.

    Article  PubMed  Google Scholar 

  11. Neragi-Miandoab S, Richards WG, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg. 2008;6:293–7.

    Article  PubMed  Google Scholar 

  12. Verma V, Ahern C, Berlind CG, Lindsay WD, Shabason J, Sharma S, Culligan MJ, Grover S, Friedberg JS, Simone CB. Survival by histologic subtype of malignant pleural mesothelioma and the impact of surgical resection on overall survival. Clin Lung Cancer. 2018;19(6):e901–12.

    Article  PubMed  Google Scholar 

  13. Alchami FS, Attanoos RL, Bamber AR. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma. J Clin Pathol. 2017;70:179–82.

    Article  PubMed  Google Scholar 

  14. Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol. 2011;6:896–904.

    Article  PubMed  Google Scholar 

  15. Allen TC. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch Pathol Lab Med. 2005;129:1415–20.

    PubMed  Google Scholar 

  16. Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008;21:1084–94.

    Article  PubMed  Google Scholar 

  17. Neumann V, Gunthe S, Mulle KM, Fischer M. Malignant mesothelioma—German Mesothelioma Register 1987–1999. Int Arch Occup Environ Health. 2001;74:383–95.

    Article  CAS  PubMed  Google Scholar 

  18. Van Gelder T, Damhuis RA, Hoogsteden HC. Prognostic factors and survival of malignant pleural mesothelioma. Eur Respir J. 1994;7:1035–8.

    PubMed  Google Scholar 

  19. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south East England: clinicopathological experience of 272 cases. Thorax. 1997;52:507–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Galateau-Salle F, Churg A, Roggli V, Travis WD, on behalf of the World Health Organization Committee for Tumors of the Pleura. The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J Thorac Oncol. 2016;11(2):142–54.

    Article  PubMed  Google Scholar 

  21. Marchewsky AM, LeStang N, Hiroshima K, Pelosi G, Attanoos R, Churg A, Chirieac L, Dacic S, Husain A, Khoor A, Klebe S, Lantuejoul S, Roggli V, Vignaud J-M, Weynard B, Sauter J, Henderson D, Nabeshima K, Galateau-Salle F. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Hum Pathol. 2017;67:160–8.

    Article  Google Scholar 

  22. Dardick I, Jabi M, McCaughey WT, Deodhare S, van Nostrand AW, Srigley JR. Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum. Ultrastruct Pathol. 1987;11:503–33.

    Article  CAS  PubMed  Google Scholar 

  23. Oury TD, Hammar SP, Roggli VL. Ultrastructural features of diffuse malignant mesotheliomas. Hum Pathol. 1998;29:1382–92.

    Article  CAS  PubMed  Google Scholar 

  24. MacDougall DB, Wang SE, Zidar BL. Mucin-positive epithelial mesothelioma. Arch Pathol Lab Med. 1992;116:874–80.

    CAS  PubMed  Google Scholar 

  25. McCaughey WT, Colby TV, Battifora H, Churg A, Corson JM, Greenberg SD, Grimes MM, Hammar S, Roggli VL, Unni KK. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian mesothelioma panel. Mod Pathol. 1991;4:342–53.

    CAS  PubMed  Google Scholar 

  26. Bedrossian CW. Diagnostic problems in serous effusions. Diagn Cytopathol. 1998;19:131–7.

    Article  CAS  PubMed  Google Scholar 

  27. Rao R. Mesothelioma. In: Shidham V, Atkinson BF, editors. Cytopathologic diagnosis of serous fluids. Philadelphia: Saunders; 2007. p. 107–13.

    Google Scholar 

  28. Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010;38:874–9.

    Article  CAS  PubMed  Google Scholar 

  29. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:106–9.

    Article  CAS  PubMed  Google Scholar 

  30. Sherman ME, Mark EJ. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma. Arch Pathol Lab Med. 1990;114:845–51.

    CAS  PubMed  Google Scholar 

  31. Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13:174–84.

    Article  PubMed  Google Scholar 

  32. Anttila S. Epithelioid lesions of the serosa. Arch Pathol Lab Med. 2012;136:241–52.

    Article  PubMed  Google Scholar 

  33. Di Loreto C, Publisi F, Di Laurio V, Damani G, Beltrami A. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett. 1998;124:72–8.

    Article  Google Scholar 

  34. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol. 1998;22:1203–14.

    Article  CAS  PubMed  Google Scholar 

  35. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598–606.

    Article  CAS  PubMed  Google Scholar 

  36. Attanoos RL, Galateau-Salle F, Gibbs AR, Muller S, Ghandour F, Dojcinov SD. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma. Histopathology. 2002;41:42–9.

    Article  CAS  PubMed  Google Scholar 

  37. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology. 2002;40:237–44.

    Article  CAS  PubMed  Google Scholar 

  38. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol. 2002;15:6–10.

    Article  PubMed  Google Scholar 

  39. Lugli A, Forster Y, Haas P, Nocito A, Bucher C, Bissig H, Mirlacher M, Storz M, Mihatsch MJ, Sauter G. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol. 2003;34:994–1000.

    Article  CAS  PubMed  Google Scholar 

  40. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003;27:150–8.

    Article  PubMed  Google Scholar 

  41. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16:192–7.

    Article  PubMed  Google Scholar 

  42. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105–10.

    Article  CAS  PubMed  Google Scholar 

  43. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 2005;36:372–80.

    Article  CAS  PubMed  Google Scholar 

  44. Ordonez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol. 2005;36:1163–7.

    Article  CAS  PubMed  Google Scholar 

  45. Barnetson RJ, Burnett RA, Downie I, Harper CM, Roberts F. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol. 2006;125:67–76.

    Article  CAS  PubMed  Google Scholar 

  46. Ordonez NG. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases. Mod Pathol. 2006;19:373–83.

    Article  PubMed  Google Scholar 

  47. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006;19:34–48.

    Article  CAS  PubMed  Google Scholar 

  48. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleaural disease: a systematic review of published reports. Histopathology. 2006;49:561–8.

    Article  CAS  PubMed  Google Scholar 

  49. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology. 2006;48:223–32.

    Article  CAS  PubMed  Google Scholar 

  50. Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, Kussick SJ, Gown AM. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19:514–23.

    Article  CAS  PubMed  Google Scholar 

  51. Padgett DM, Cathro HP, Wick MR, Mills SE. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol. 2008;32:123–7.

    Article  PubMed  Google Scholar 

  52. Duhig EE, Kalpakos L, Yang IA, Clarke BE. Mesothelial markers in high-grade breast carcinoma. Histopathology. 2011;59:957–64.

    Article  PubMed  Google Scholar 

  53. Comin CE, Novelli L, Cavazza A, Rotellini M, Cianchi F, Messerini L. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40, and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma. Tumori. 2014;100(5):559–67.

    PubMed  Google Scholar 

  54. Ordonez NG, Sahin AA. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. Hum Pathol. 2014;45:1529–40.

    Article  CAS  PubMed  Google Scholar 

  55. Khoor A, Whitsett JA, Stahlman MT, Olson SJ, Cagle PT. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol. 1999;30:695–700.

    Article  CAS  PubMed  Google Scholar 

  56. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20–5.

    Article  CAS  PubMed  Google Scholar 

  57. Mawas AS, Amatya VJ, Kushitani K, Kai Y, Miyata Y, Okada M, Takeshima Y. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung. Sci Rep. 2018;8:134.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Soini Y, Kinnula V, Kahlos K, Pääkkö P. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol. 2006;59:250–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ohta Y, Sasaki Y, Saito M, Kushima M, Takimoto M, Shiokawa A, Ota H. Claudin-4 as a marker for distinguishing malignant mesothelioma from lung carcinoma and serous adenocarcinoma. Int J Surg Pathol. 2013;21(5):493–501.

    Article  PubMed  Google Scholar 

  60. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19:417–28.

    Article  PubMed  Google Scholar 

  61. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol. 2004;35:697–710.

    Article  CAS  PubMed  Google Scholar 

  62. Butnor KJ, Nicholson AG, Allred DC, Zander DS, Henderson DW, Barrios R, Haque AK, Allen TC, Killen DE, Cagle PT. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med. 2006;130:823–7.

    CAS  PubMed  Google Scholar 

  63. Hu Y, Hartmann A, Stoehr C, Zhang S, Wang M, Tacha A, Montironi R, Lopez-Beltran A, Cheng L. PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. J Clin Pathol. 2012;65:254–6.

    Article  PubMed  Google Scholar 

  64. Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627–35.

    Article  PubMed  Google Scholar 

  65. Xing D, Banet N, Sharma R, Vang R, Ronnett BM, Illei PB. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study. Hum Pathol. 2018;72:160–6.

    Article  CAS  PubMed  Google Scholar 

  66. Ordonez NG. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol. 2013;26:553–62.

    Article  CAS  PubMed  Google Scholar 

  67. Comin CE, Saieva C, Messerini L. H-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31:1139–48.

    Article  PubMed  Google Scholar 

  68. Tandon RT, Jimenez-Cortez Y, Taub R, Borczuk AC. Immunohistochemistry in peritoneal mesothelioma. A single-center experience of 244 cases. Arch Pathol Lab Med. 2018;142:236–42.

    Article  CAS  PubMed  Google Scholar 

  69. Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol. 1985;121:235–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol. 2001;25:610–7.

    Article  CAS  PubMed  Google Scholar 

  71. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern. Histopathology. 2001;39:584–8.

    Article  CAS  PubMed  Google Scholar 

  72. Klebe S, Brownlee NA, Mahar A, Burchette JL, Sporn TA, Vollmer RT, Roggli VL. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23:470–9.

    Article  PubMed  Google Scholar 

  73. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Fujii T, Zen Y, Sato Y, Sasaki M, Enomae M, Minato H, Masuda S, Uehara T, Katsuyama T, Nakanuma Y. Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. Mod Pathol. 2008;21:125–30.

    Article  CAS  PubMed  Google Scholar 

  75. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology. 2005;46:396–402.

    Article  CAS  PubMed  Google Scholar 

  76. Pan CC, Chen PC, Chou TY, Chiang H. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol. 2003;34:1155–62.

    Article  CAS  PubMed  Google Scholar 

  77. Zhang PJ, Goldblum JR, Pawel BR, Fisher C, Pasha TL, Barr FG. Immunophenotype of desmoplastic small round cell tumors as detected in cases with EWS-WT1 gene fusion product. Mod Pathol. 2003;16:229–35.

    Article  PubMed  Google Scholar 

  78. Granville L, Laga AC, Allen TC, Dishop M, Roggli VL, Churg A, Zander DS, Cagle PT. Review and update of uncommon primary pleural tumors: a practical approach to diagnosis. Arch Pathol Lab Med. 2005;129:1428–43.

    PubMed  Google Scholar 

  79. Butnor KJ, Sporn TA, Hammar SP, Roggli VL. Well-differentiated papillary mesothelioma. Am J Surg Pathol. 2001;25:1304–9.

    Article  CAS  PubMed  Google Scholar 

  80. Foyle A, Al-Jabi M, McCaughey WT. Papillary peritoneal tumors in women. Am J Surg Pathol. 1981;5:241–9.

    Article  CAS  PubMed  Google Scholar 

  81. Galateau-Salle F, Vignaud JM, Burke L, Gibbs A, Brambilla E, Attanoos R, Goldberg M, Launoy G. Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases. Am J Surg Pathol. 2004;28:534–40.

    Article  PubMed  Google Scholar 

  82. Sane AC, Roggli VL. Curative resection of a well-differentiated papillary mesothelioma of the pericardium. Arch Pathol Lab Med. 1995;119:266–7.

    CAS  PubMed  Google Scholar 

  83. Xiao SY, Rizzo P, Carbone M. Benign papillary mesothelioma of the tunica vaginalis testis. Arch Pathol Lab Med. 2000;124:143–7.

    CAS  PubMed  Google Scholar 

  84. Asioli S, Dal Piaz G, Damiani S. Localised pleural malignant mesothelioma. Report of two cases simulating pulmonary carcinoma and review of the literature. Virchows Arch. 2004;445:206–9.

    Article  PubMed  Google Scholar 

  85. Espinal-Witter R, Servais EL, Klimstra DS, Lieberman MD, Yantiss RK. Localized intrapancreatic malignant mesothelioma: a rare entity that may be confused with other pancreatic neoplasms. Virchows Arch. 2010;456:455–61.

    Article  PubMed  Google Scholar 

  86. Onat A, Berktin K, Kapanci Y. Localized pleural mesothelioma of epithelial type and malignant nature. Report of a case. Dis Chest. 1963;44:649–52.

    Article  CAS  PubMed  Google Scholar 

  87. Sasaki M, Araki I, Yasui T, Kinoshita M, Itatsu K, Nojima T, Nakanuma Y. Primary localized malignant biphasic mesothelioma of the liver in a patient with asbestosis. World J Gastroenterol. 2009;15:615–21.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005;129:1421–7.

    PubMed  Google Scholar 

  89. Churg A, Colby TV, Cagle P, Corson J, Gibbs AR, Gilks B, Grimes M, Hammar S, Roggli V, Travis WD. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183–200.

    Article  CAS  PubMed  Google Scholar 

  90. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231–8.

    Article  CAS  PubMed  Google Scholar 

  91. Churg A, Sheffield BS, Galateau-Salle F. New markers for separating benign from malignant mesothelial proliferations. Are we there yet? Arch Pathol Lab Med. 2016;140:318–21.

    Article  CAS  PubMed  Google Scholar 

  92. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215–20.

    Article  CAS  PubMed  Google Scholar 

  93. Shen J, Pinkus GS, Deshpande V, Cibas ES. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol. 2009;131:516–23.

    Article  CAS  PubMed  Google Scholar 

  94. Wu M, Sun Y, Li G, Desman G, Wang B, Gil J, Burstein DE. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol. 2007;128:783–7.

    Article  PubMed  Google Scholar 

  95. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21:742–7.

    Article  CAS  PubMed  Google Scholar 

  96. Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Nonomura A. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60:395–9.

    Article  PubMed  Google Scholar 

  97. Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant mesothelioma diagnosis: ROC analysis of the two tests. Pathol Int. 2016;66:563–70.

    Article  CAS  PubMed  Google Scholar 

  98. Ito T, Hamasaki M, Matsumoto S, Hiroshima K, Tsujimura T, Kawai T, Shimao Y, Marutsuka K, Moriguchi S, Maruyama R, Miyamoto S, Nabeshima K. p16/CDKN2A FISH in differentiation of diffuse malignant peritoneal mesothelioma from mesothelial hyperplasia and epithelial ovarian cancer. Am J Clin Pathol. 2015;143:830–8.

    Article  CAS  PubMed  Google Scholar 

  99. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9:2108–13.

    CAS  PubMed  Google Scholar 

  100. McGregor SM, McElherne J, Minor A, Keller-Ramey J, Dunning R, Husain AN, Vigneswaran W, Fitzpatrick C, Krausz T. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. Hum Pathol. 2017;60:86–94.

    Article  PubMed  CAS  Google Scholar 

  101. Tochigi N, Attanoos R, Chirieac LR, Allen TC, Cagle PT, Dacic S. p16 deletion in sarcomatoid tumors of the lung and pleura. Arch Pathol Lab Med. 2013;137:632–6.

    Article  PubMed  Google Scholar 

  102. Wu D, Hiroshima K, Yusa T, Ozaki D, Koh E, Sekine Y, Matsumoto S, Nabeshima K, Sato A, Tsujimura T, Yamakawa H, Tada Y, Shimada H, Tagawa M. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma. Ann Diagn Pathol. 2017;26:31–7.

    Article  PubMed  Google Scholar 

  103. Wu D, Hiroshima K, Matsumoto S, Nabeshima K, Yusa T, Ozaki D, Fujino M, Yamakawa H, Nakatani Y, Tada Y, Shimada H, Tagawa M. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013;139:39–46.

    Article  CAS  PubMed  Google Scholar 

  104. Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM, Churg A. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39(7):977–82.

    Article  PubMed  Google Scholar 

  105. Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer. 2017;104:98–105.

    Article  PubMed  Google Scholar 

  106. Hamasaki M, Matsumoto S, Abe S, Hamatake D, Kamei T, Hiroshima K, Kawahara K, Sato A, Tsujimura T, Nakatani Y, Yoshida Y, Iwasaki A, Nabeshima K. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma. Lung Cancer. 2016;99:155–61.

    Article  PubMed  Google Scholar 

  107. Krasinskas AM, Bartlett DL, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010;23:531–8.

    Article  CAS  PubMed  Google Scholar 

  108. Singhi AD, Krasinskas AM, Choudry HA, Bartlett DL, Pingpank JF, Zeh HJ, Luvison A, Fuhrer K, Bahary N, Seethala RR, Dacic S. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016;29:14–24.

    Article  CAS  PubMed  Google Scholar 

  109. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Sabahattin C, Tanji M, Gaudino G, Yang H, Carbone M. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2012;43(10):1022–5.

    Article  CAS  Google Scholar 

  110. Cheung M, Talarchek J, Schindeler K, Saraiva E, Penney LS, Ludman M, Testa JR. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet. 2013;206:206–10.

    Article  CAS  PubMed  Google Scholar 

  111. Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong L, McGillivray B, Asrat M-J, Davidorf FH, Abdel-Rahman MH. Expanding the clinical phenotype of hereditary BAP1 cancer syndrome, reporting three new cases. Genes Chromosomes Cancer. 2014;53(2):177–82.

    Article  CAS  PubMed  Google Scholar 

  112. Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR. Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res. 2016;76(2):206–15.

    Article  CAS  PubMed  Google Scholar 

  113. Betti M, Casalone E, Ferrante D, Romanelli A, Grosso F, Guarrera S, Righi L, Vatrano S, Pelosi G, Libener R, Mirabelli D, Boldorini R, Casadio C, Papotti M, Matullo G, Magnani C, Dianzani I. Inference of germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer. 2015;54:51–62.

    Article  CAS  PubMed  Google Scholar 

  114. Cicognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G, Murer B, Barbareschi M, Giuliani S, Cavazza A, Marchetti G, Vermi W, Facchetti F. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043–57.

    Article  CAS  Google Scholar 

  115. McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol. 2015;46:1670–8.

    Article  CAS  PubMed  Google Scholar 

  116. Righi L, Duregon E, Vatrano S, Izzo S, Giorcelli J, Rondon-Lagos M, Ascoli V, Ruffini E, Ventura L, Volante M, Papotti M, Scagliotti GV. BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study. J Thorac Oncol. 2016;11(11):2006–17.

    Article  PubMed  Google Scholar 

  117. Leblay N, Lepetre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Salle F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay J, Figeac M, Glehen O, Gilly F-N, Foll M, Fernandez-Cuesta L, Brevet M. BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol. 2017;12(4):724–33.

    Article  PubMed  Google Scholar 

  118. Travis WD. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med. 2010;134:1645–58.

    PubMed  Google Scholar 

  119. Miettinen M, Limon J, Niezabitowski A, Lasota J. Patterns of keratin polypeptides in 110 biphasic, monophasic, and poorly differentiated synovial sarcomas. Virchows Arch. 2000;437:275–83.

    Article  CAS  PubMed  Google Scholar 

  120. Aubry MC, Bridge JA, Wickert R, Tazelaar HD. Primary monophasic synovial sarcoma of the pleura: five cases confirmed by the presence of SYT-SSX fusion transcript. Am J Surg Pathol. 2001;25:776–81.

    Article  CAS  PubMed  Google Scholar 

  121. Gaertner E, Zeren EH, Fleming MV, Colby TV, Travis WD. Biphasic synovial sarcomas arising in the pleural cavity. A clinicopathologic study of five cases. Am J Surg Pathol. 1996;20:36–45.

    Article  CAS  PubMed  Google Scholar 

  122. Litzky LA. Pulmonary sarcomatous tumors. Arch Pathol Lab Med. 2008;132:1104–17.

    PubMed  Google Scholar 

  123. de Leeuw B, Balemans M, Olde Weghuis D, Geurts van Kessel A. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum Mol Genet. 1995;4:1097–9.

    Article  PubMed  Google Scholar 

  124. Khalidi HS, Medeiros LJ, Battifora H. Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma. Am J Clin Pathol. 2000;113:649–54.

    Article  CAS  PubMed  Google Scholar 

  125. Mangano WE, Cagle PT, Churg A, Vollmer RT, Roggli VL. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol. 1998;110:191–9.

    Article  CAS  PubMed  Google Scholar 

  126. Stout A. Tumors of the pleura. Harlem Hosp Bull. 1971;5:54–7.

    Google Scholar 

  127. Cantin R, Al-Jabi M, McCaughey WT. Desmoplastic diffuse mesothelioma. Am J Surg Pathol. 1982;6:215–22.

    Article  CAS  PubMed  Google Scholar 

  128. Wilson GE, Hasleton PS, Chatterjee AK. Desmoplastic malignant mesothelioma: a review of 17 cases. J Clin Pathol. 1992;45:295–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Attanoos RL, Dojcinov SD, Webb R, Gibbs AR. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology. 2000;37:224–31.

    Article  CAS  PubMed  Google Scholar 

  130. Hinterberger M, Reineke T, Storz M, Weder W, Vogt P, Moch H. D2-40 and calretinin—a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 2007;20:248–55.

    Article  CAS  PubMed  Google Scholar 

  131. Kenmotsu H, Ishii G, Nagai K, Nakao M, Kawase A, Kojika M, Murata Y, Nishiwaki Y, Ochiai A. Pleomorphic carcinoma of the lung expressing podoplanin and calretinin. Pathol Int. 2008;58:771–4.

    Article  CAS  PubMed  Google Scholar 

  132. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int. 2008;58:75–83.

    Article  CAS  PubMed  Google Scholar 

  133. Lucas DR, Pass HI, Madan SK, Adsay NV, Wali A, Tabaczka P, Lonardo F. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003;42:270–9.

    Article  CAS  PubMed  Google Scholar 

  134. Lewis JS, Ritter JH, El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. Mod Pathol. 2005;18:1471–81.

    Article  CAS  PubMed  Google Scholar 

  135. Tsuta K, Kato Y, Tochigi N, Hoshino T, Takeda Y, Hosako M, Maeshima AM, Asamura H, Kondo T, Matsuno Y. Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma. Appl Immunohistochem Mol Morphol. 2009;17:126–30.

    Article  CAS  PubMed  Google Scholar 

  136. Koss MN, Hochholzer L, Frommelt RA. Carcinosarcomas of the lung: a clinicopathologic study of 66 patients. Am J Surg Pathol. 1999;23:1514–26.

    Article  CAS  PubMed  Google Scholar 

  137. Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Takeshima Y. MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Mod Pathol. 2017;30:672–81.

    Article  CAS  PubMed  Google Scholar 

  138. Pelosi G, Sonzogni A, De Pas T, Galetta D, Veronesi G, Spaggiari L, Manzotti M, Fumagalli C, Bresaola E, Nappi O, Viale G, Rosai J. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol. 2010;18:103–20.

    Article  PubMed  Google Scholar 

  139. Rossi G, Cavazza A, Sturm N, Migaldi M, Facciolongo N, Longo L, Maiorana A, Brambilla E. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol. 2003;27:311–24.

    Article  PubMed  Google Scholar 

  140. Berg KB, Churg A. GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung. Am J Surg Pathol. 2017;41(9):1221–5.

    Article  PubMed  Google Scholar 

  141. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135:92–109.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

    Sisko Anttila

Authors
  1. Sisko Anttila
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sisko Anttila .

Editor information

Editors and Affiliations

  1. Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

    Sisko Anttila

  2. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Paolo Boffetta

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anttila, S. (2020). Malignant Mesothelioma: Pathology. In: Anttila, S., Boffetta, P. (eds) Occupational Cancers. Springer, Cham. https://doi.org/10.1007/978-3-030-30766-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-30766-0_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-30765-3

  • Online ISBN: 978-3-030-30766-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation